Compare Research Peptides

Select 2 peptides to compare benefits, dosage, administration routes, mechanisms, and side effect profiles side by side.

Peptide 1

Peptide 2

	Dihexa N-hexanoic-Tyr-Ile-(6) aminohexanoic amide Sign up to track	P21 DTHFPIC Dipeptide Sign up to track
Evidence Grade	DEvidenceGrade DTheoretical or in-vitro only; no meaningful independent human evidence	DEvidenceGrade DTheoretical or in-vitro only; no meaningful independent human evidence
Regulatory	Research OnlyResearch OnlyNo regulatory approval in any major jurisdiction; for research use only	Research OnlyResearch OnlyNo regulatory approval in any major jurisdiction; for research use only
Category	Cognitive Enhancement	Cognitive Enhancement
Key Benefits	•Dramatically improves cognitive function •Promotes neurogenesis •Enhances memory formation •May reverse cognitive decline +2 more	•Promotes hippocampal neurogenesis •Improves learning and memory •Neuroprotective effects •May enhance focus +2 more
Dosage	0.25-2 mg mg	10-20 mg mg
Frequency	Daily or every other day	Daily
Administration	SubcutaneousIntranasal	SubcutaneousIntranasal
Mechanism	Dihexa is an oligopeptide drug with remarkable cognitive enhancement properties. It is 7 orders of magnitude more potent than BDNF and shows promise for neurodegenerative diseases.	P21 is a nootropic peptide derived from CNTF (Ciliary Neurotrophic Factor). It promotes neurogenesis, especially in the hippocampus, and may improve learning and memory.
Side Effects / Risks	Not specified	Not specified
Research Status	Research compound - Phase 1 clinical trials	Research compound